Covance Is Now Labcorp Drug Development

We are one global company innovating for millions – together, continuing to bring you more advanced medical breakthroughs.

Learn More

Advancing Healthcare Across Asia Pacific

Reimagine comprehensive drug development and diagnostic solutions customized to meet your unique needs with our integrated services across the Asia Pacific region.

Contact Us

Gain scientific insights to move your program forward to improve health on a global scale.

Work with a globally connected network to achieve globally combinable data.

Form a strategic partnership—tailored to your specific needs—at any stage of your development journey with a full-service provider.

Your source for a customized suite of drug development solutions in APAC

By the Numbers

1998 first APAC facility
15 Countries with facilities
7,000+ Employees

An established global partnership for efficient drug development

We know how to advance your program in Asia Pacific, a preferred destination for clinical trials with its high-quality infrastructure and skilled talent. Since we established our first facilities in 1998, we’ve grown across 15 countries and regions with 7,000+ employees.

As your partner, we offer our specialized clinical trial centers and networks in APAC, so you can receive globally acceptable data, meet regulatory requirements and improve your cost efficiencies. Together, we can drive your drug development forward and make a real impact on people’s lives.


We’re connected across Asia Pacific to meet your needs.

We’re here to support you at any stage of your drug development journey. Whether you are a nimble biotech or a large organization, we know how to support your mission and get you the solutions you need—at the right time and place.

Have Questions?

  • What is an FSP?

    FSP stands for functional service provider and is about delivering customized global solutions that enable clients to efficiently manage their clinical trial portfolio. This includes putting quality people, intelligent processes, and deep technical expertise in place to work directly on a client’s business. An increasing number of pharmaceutical and biotech companies are turning toward this model to decrease their overhead and make their operations leaner and more efficient. Labcorp FSPx® is the functional service provider you can rely on to deliver customizable solutions through strong collaboration and commitment to quality.

  • How does Labcorp Drug Development utilize proprietary data to improve clinical study outcomes?

    Only Labcorp Drug Development combines one of the world’s largest sources of de-identified lab results and patient intelligence data with investigator data from the majority of global clinical trials, providing insights to increase efficiencies and effectiveness in clinical drug development.

    Using Labcorp’s real-world, de-identified clinical laboratory data on over 150 million patients, we can assess populations who meet your protocol’s eligibility criteria and accurately model the impact that the protocol inclusion/exclusion criteria will have on the patient pool size.

    Labcorp Central Labs Data – Labcorp Drug Development generates more clinical trial data than anyone else in the world. Our global proprietary data helps us predict future investigator performance and capacity to run multiple studies.

    Patient Direct – we have access to ~150 million patients and have a rapidly growing database of people who have given us permission to reach out directly to them for participation in clinical studies. 

  • What are the benefits of partnership for a nimble biotech?

    We offer solutions, services and resources, designed specifically for agile biotech companies. We provide personalized attention and give your team access to specialized expertise—scientific, operational, regulatory and therapeutic—that adapts to the way you work to champion your success and advance your program, at any stage in your drug development journey. 

  • What is programmatic outsourcing model and its benefits?

    A programmatic model integrates a set of pre-defined studies and services to support the development of a molecule. The result is increased flexibility, efficiency and enhanced insight—saving valuable time and maximizing asset value more expeditiously.

Browse our educational materials in the APAC Education Center to gain new insights from our key subject matter experts.

Educational Insights

Challenges and Best Practices in Supporting Clinical Bioanalysis in China

Challenges and Best Practices in Supporting Clinical Bioanalysis in China

Articles
In the rapidly evolving Chinese research and development (R&D) landscape, there are several key considerations for effectively supporting global clinical trials with regulated bioanalysis in China. This white paper discusses the current status of bioanalysis in the region, in-country support and local guidance strategies to combat potential challenges in supporting clinical bioanalysis within China.
Read More
APAC Clinical Trials in COVID-19 Pandemic-Best Practices and Expectations for Continuity in Global Drug Development

APAC Clinical Trials in COVID-19 Pandemic-Best Practices and Expectations for Continuity in Global Drug Development

Articles
This article talks about the best practices adopted by Covance APAC during COVID-19 pandemic - The path for recovery was not trivial - it required innovative problem solving and the coordinated efforts of cross-functional teams. Learn about the steps the Covance APAC teams took to: ensure continuity of drug development; set sponsors' expectations for trial readiness in APAC; and develop best practices for a recovery model, which could be implemented beyond APAC to support global trials in the US and EU.
Read More

Let's start a conversation

Contact Us